Development and Comparison of Two Immuno-disaggregation Based Bioassays for Cell Secretome Analysis

Detection and Quantification of Exhaled Breath Condensate and Dyspnea Correlation in Stable COPD: A Proof-of-Concept Study

BACKGROUND

The existing research data are still not able to provide an answer to the issue of the correlation between dyspnea and inflammation in stable chronic obstructive pulmonary disease (COPD). The purpose of this study was to assess the possible relationship between a noninvasive medium called the exhaled breath condensate (EBC) and dyspnea in stable COPD patients.

METHODS

A group of ten patients (five with and five without COPD) participated. The exhaled breath condensate was analyzed for the first time with a high-resolution device, the Accusizer 780SIS. The particle concentration of the EBC was measured and correlated with tools used for dyspnea assessment and clinical picture (modified Research Council dyspnea scale, mMRC scale; modified Borg dyspnea scale; and COPD Assessment Test, CAT scale). Because of the very small sample size (Ν = 10), bootstrapping method (applying 5000 bootstrap resamples with 95% confidence intervals) was used to derive robust estimates of standard errors and confidence intervals for estimates of means and correlation coefficients. Bootstrap works well in small sample sizes by ensuring the correctness of tests.

RESULTS

The bootstrap means of EBC, mMRC, Borg, and CAT scales were 223863.43 (95% CI, 151308.58-297603.04), 1.30 (95% CI, 0.70-1.90), 1.55 (95% CI, 0.55-2.80), and 6.70 (95% CI, 4.80-8.60), respectively. The bootstrap Pearson's correlation coefficient (r) of EBC, mMRC, Borg, and CAT scales were 0.889 (95% CI, 0.716-0.979), 0.641 (95% CI, -0.542-0.887), and 0.569 (95% CI, -0.184-0.912), respectively.

CONCLUSIONS

The effect size of the correlations is significantly high at the 0.01 level (two-tailed) between the EBC and the mMRC scale, less high at the 0.05 level (two-tailed) between the EBC and the Borg dyspnea scale and marginally with the CAT scale, respectively. Studies with larger samples will be needed to obtain more reliable results.

Design and synthesis of NQO1 responsive fluorescence probe and its application in bio-imaging for cancer diagnosis

As an over-expressed flavoprotein in several kinds of tumor cells, NAD(P)H: quinone oxidoreductase-1 (NQO1) is considered as a potent biomarker in early-stage cancer diagnosis. Developing a fast, selective and sensitive method of monitoring NQO1 on cellular level will greatly promote cancer diagnosis in clinical practice. In this paper, a fast NQO1 responsive fluorescence probe SYZ-30 containing quinone acid and 7-nitro-2,1,3-benzoxadiazole (NBD) fluorophore is constructed. The probe could selectively respond to NQO1 and rapidly emit strong fluorescence in vitro within only 5 min. Notably, the peak fluorescent intensities at 550 nm showed a linear relationship with NQO1 concentrations in the range of 3-30 ng/ml and limit of detection (LOD) was 0.0667 ng/ml. Furthermore, it was validated that the probe has good biocompatibility and could be applied for bio-imaging in NQO1 over-expressed cancer cells, together with its mitochondria targeting ability. Importantly, confocal fluorescence imaging confirmed the NQO1 detection ability on cellular level, which can be used for real-time detection of several cancer subtypes like adenocarcinoma. To conclude, the probe is rapidly responsive, highly sensitive and selective which will potentially become a practical tool for early cancer detection and diagnosis.